Cargando…

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway

BACKGROUND: The lack of effective treatments for gliomas makes them a significant health problem and highlights the need for the development of novel and innovative treatment approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konkankit, Veerauo V, Kim, Won, Koya, Richard C, Eskin, Ascia, Dam, Mai-Anh, Nelson, Stanley, Ribas, Antoni, Liau, Linda M, Prins, Robert M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229551/ https://www.ncbi.nlm.nih.gov/pubmed/22060015 http://dx.doi.org/10.1186/1479-5876-9-192

Ejemplares similares

The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability
por: Henkler, Frank, et al.
Publicado: (2005)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
Publicado: (1996)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

ALKing the flames of lung cancer immunosensitivity
por: Bayliss, Richard, et al.
Publicado: (2023)

Understanding the role of Fas-Fas ligand system in bone
por: Marusic, Ana, et al.
Publicado: (2012)

Differential expressions of Fas and Fas ligand in human placenta.
por: Roh, Cheong-Rae, et al.
Publicado: (2002)

Soluble Fas and the −670 Polymorphism of Fas in Lupus Nephritis
por: Bollain-y-Goytia, Juan José, et al.
Publicado: (2014)

The Fas/FasL System in Reproduction: Survival and Apoptosis
por: Mor, Gil, et al.
Publicado: (2002)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis
por: Owen-Schaub, Laurie B., et al.
Publicado: (1998)

Apoptosis role of FAS/FAS ligand system in the regulation of myelopoiesis.
por: Alenzi, Faris Q., et al.
Publicado: (2005)

Role of the Fas/FasL pathway in HIV or SIV disease
por: Poonia, Bhawna, et al.
Publicado: (2009)

Prognostic value of the Fas/Fas ligand system in breast cancer
por: Bębenek, Marek, et al.
Publicado: (2013)

Fas–Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis
por: Volpe, Elisabetta, et al.
Publicado: (2016)

FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection
por: Mohammadi, Asadollah, et al.
Publicado: (2015)

Involvement of Fas/FasL pathway in the murine model of atopic dermatitis
por: Bień, Karolina, et al.
Publicado: (2017)

The relationship between Fas and Fas ligand gene polymorphism and preeclampsia risk
por: Wang, Tingting, et al.
Publicado: (2019)

Fas/FasL Contributes to HSV-1 Brain Infection and Neuroinflammation
por: Krzyzowska, Malgorzata, et al.
Publicado: (2021)

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
por: Bethune, Michael T., et al.
Publicado: (2018)

Plasma concentrations of soluble Fas receptors (Fas) and Fas ligands (FasL) in relation to CD4+ cell counts in HIV-1 positive and negative patients in Yaounde, Cameroon
por: Ikomey, George M, et al.
Publicado: (2012)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids
Publicado: (1995)

Impairment of Fas-ligand–caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death
por: Glukhova, Xenia A., et al.
Publicado: (2018)

Fas gets protective
por: Johnston, Nicole
Publicado: (2005)

Typhus [ti′ fəs]
Publicado: (2009)

Lupus in the Fas Lane?
por: Singh, Ajay K
Publicado: (1995)

The Economic Cost of FAS
por: Bloss, Gregory
Publicado: (1994)

Tracking the Prevalence of FAS
por: Cordero, José F., et al.
Publicado: (1994)

Intervention and the Child With FAS
por: Weiner, Lyn, et al.
Publicado: (1994)

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma
por: Ito, Y, et al.
Publicado: (2000)

Expression of Fas antigen and Fas ligand in bronchoalveolar lavage from silicosis patients.
por: Hamzaoui, Agnès, et al.
Publicado: (2003)

Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide
Publicado: (1996)

Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages
por: Kiener, Peter A., et al.
Publicado: (1997)

Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions
por: Davidson, Wendy F., et al.
Publicado: (1998)

Involvement of the Fas and Fas ligand in testicular germ cell apoptosis by zearalenone in rat
por: Jee, Youngheun, et al.
Publicado: (2010)

Dexamethasone effect on sFas/sFas ligand following cardiopulmonary bypass
por: Joashi, U, et al.
Publicado: (2001)

Disruption of Fas-Fas Ligand Signaling, Apoptosis, and Innate Immunity by Bacterial Pathogens
por: Caulfield, Adam J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0jvqjhj11auirl9oefvn8ounum